137469-86-4

Basic information

• Product Name: BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE
• Synonyms: BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE;(1,2,3,4-TETRAHYDRO-QUINOLIN-8-YL)-CARBAMIC ACID TERT-BUTYL ESTER;PMVBTAJOVLAIOD-UHFFFAOYSA-N
• CAS NO: 137469-86-4
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.32
• Product Categories: Quinolines, Quinazolines and derivatives;pharmacetical
• Mol File: 137469-86-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 338.4°Cat760mmHg
• Flash Point: 158.5°C
• Appearance: /
• Density: 1.122g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• CAS DataBase Reference: BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE(137469-86-4)
• EPA Substance Registry System: BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE(137469-86-4)

Safety Data

• Hazardous Substances Data: 137469-86-4(Hazardous Substances Data)

Usage

General Description

BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE is a chemical compound that belongs to the class of tetrahydroquinoline derivatives. It is a heterocyclic compound consisting of a quinoline ring with an amino group and a BOC (tert-butoxycarbonyl) protecting group. BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE is used in organic synthesis as a building block for the preparation of various pharmaceuticals, agrochemicals, and materials. It is also utilized as a precursor in the synthesis of peptide and oligonucleotide conjugates. BOC-8-AMINO-1,2,3,4-TETRAHYDROQUINOLINE has potential applications in medicinal chemistry and drug discovery due to its structural flexibility and biological activity.

InChI:InChI=1/C14H20N2O2/c1-14(2,3)18-13(17)16-11-8-4-6-10-7-5-9-15-12(10)11/h4,6,8,15H,5,7,9H2,1-3H3,(H,16,17)

Upstream product

• 607-35-2 8-nitroquinoline 
• 54012-92-9 8-amino-1,2,3,4-tetrahydroquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 578-66-5 8-amino quinoline 
• 137469-85-3 tert-butyl (quinolin-8-yl)carbamate 

Relevant articles and documents

Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors

The targeted regulation of LSD1, which is highly expressed in a variety of tumor cells, is a promising cancer therapy strategy. Several LSD1 inhibitors are currently under clinical evaluation, and most of these inhibitors are irreversible. Here, we report the design, synthesis and biochemical evaluation of novel tetrahydroquinoline-based reversible LSD1 inhibitors. Compounds 18s and 18x, which are selective to LSD1 over MAO-A/B, exhibit excellent LSD1 inhibition at the molecular levels with IC50 = 55 nM and 540 nM, respectively. The classic Lineweaver–Burk plots revealed that compound 18s could reversibly bind the LSD1 enzyme in a noncompetitive manner. Molecular docking was used to reveal the potential binding-mode of the compounds and interpret the structure-activity relationships. Furthermore, compounds 18s and 18x significantly inhibited proliferation (IC50 = 1.13 μM and 1.15 μM, respectively) and induced apoptosis in MGC-803 cells with high expression of LSD1. Compound 18x showed acceptable liver microsomal stability. Meanwhile, 18x did not appear to inhibit CYPs at 10 μM in vitro. Remarkably, the oral administration of compound 18x can inhibit the growth of MGC-803 xenograft tumors without significant side effects. Our findings suggest that tetrahydroquinoline-based LSD1 inhibitors deserve further investigation for the treatment of LSD1 overexpressing cancer.

Sulfonamide derivatives and drugs containing the same as the active ingredient

The present invention discloses a sulfonamide derivative represented by the following formula (1): [wherein A represents a nitrogen atom, —CH═, etc.; Z represents an oxygen atom, etc.; Ar1represents an aryl group, etc.; Ar2represents an alkyl group, etc.; Rarepresents a hydrogen atom, etc.; Rbrepresents a hydrogen atom, etc.; and Rcrepresents an alkyl group, etc.], or a salt thereof; and drugs containing the derivative or a salt thereof as an active ingredient. This compound exhibits radical scavenging action, gastric mucous secretion augmenting action, and anti-HP action, and thus is effective as a peptic ulcer therapeutic agent.